Lancet publishes safety trial results for Yuhan's 3rd gen. cancer drug
IndustryOct 4, 2019
The results of phase 1 and 2 clinical studies for Yuhan’s cancer drug lazertinib, suggesting that it has a “tolerable” safety profile and warrants further clinical investigation, were published in the prestigious journal the Lancet Oncology, the company said Friday.The Lancet, founded in 1823, is an international weekly medical journal.Lazertinib is an irreversible, third-generation, mutant-selective, EGFR tyrosine kinase inhibitor. Yuhan hopes it can provide another option for